UNSPSC 51385404: Cinchophen lithium

This classification denotes a nonsteroidal antiinflammatory drug C16H10NO2.Li, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 17Z71O8Z3D, chemically known as 4-quinolinecarboxylic acid, 2-phenyl-, lithium salt (1:1), but more generally known as cinchophen lithium, which bears US NIH Compound Identifier 71300649. European Medicines Agency schedules Cinchophen lithium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01307MIG.

Most nations, for tariff and trade purposes, schedule cinchophen lithium under HS 29334910 and SITC 51575. As of Q4 2014, CINCHOPHEN LITHIUM remains US FDA's Preferred Term for this commodity. SMILES: [LI+].C1CCC(CC1)C2CC(C3CCCCC3N2)C(=O)[O-].

UNSPSC 51385404 Cinchophen lithium is a Commodity code that does not map to the state and local opportunities recently posted under it. The three recent solicitations include procurements for naloxone and drug deactivation systems (Seminole County, Florida), direct-to-manufacturer prescription programs (Texas Health and Human Services Commission), and generic multi-source pharmaceuticals and OTC products (Minnesota Multistate Cooperative Purchasing Alliance). None of these opportunities involve cinchophen lithium or compounds chemically related to it. The code shows little relevant recent activity, and the mismatch between the nominal commodity name and the actual work being solicited suggests that the opportunities may have been tagged incorrectly or that cinchophen lithium is not currently a focus of state and local procurement.

The geographic spread of the three posted opportunities spans Florida, Texas, and Minnesota, with the Minnesota RFP representing a multistate cooperative purchasing vehicle that extends to Oregon. The issuing bodies include a county health department, a state health and human services commission, and a multistate cooperative purchasing alliance administered by a state department of administration. Seminole County's IFB for naloxone and drug deactivation systems closed on July 26, 2023, with quarterly deliveries to a county health facility. The Texas HHS Commission's RFI on direct-to-manufacturer prescriptions was posted April 3, 2026, as a market intelligence tool to inform future RFP development. The Minnesota MMCAP RFP for generic pharmaceuticals and OTC products, posted January 20, 2026, with proposals due March 26, 2026, established contracts effective July 1, 2026, across participating state and local facilities, requiring vendors to work through three authorized wholesalers and maintain cGMP and Drug Supply Chain Security Act compliance.